Company intelligence / Profile preview

Mondego Bio

Ownership: Private
Development stage: Other

Overview

Mondego Bio has selected ZE00-0388, a highly selective PTPN2 inhibitor, as its lead clinical candidate. Preclinical data demonstrated 80.6% inhibition of colon carcinoma growth in mouse models, with 91% inhibition when combined with PD-1 blockers. The compound showed an acceptable safety profile and oral bioavailability.[1][4]

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

ZE00-0388

Preclinical

1 more asset in the full pipeline.

Partnerships

Expert Systems (strategic, scientific, and technological support)

Beyond the preview

Go deeper on Mondego Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mondego Bio.